Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...

BKV Corporation (NYSE: BKV) ("BKV" or the "Company") today announced that it will report its third quarter 2024 operational ...

BKV Corporation (NYSE: BKV) (“BKV” or the “Company”) today announced that it will report its third quarter 2024 operational and financial results before markets open on Tuesday ...

DENVER, October 30, 2024--(BUSINESS WIRE)--BKV Corporation (NYSE: BKV) ("BKV" or the "Company") today announced that it will report its third quarter 2024 operational and financial results before ...

DENVER--(BUSINESS WIRE)--BKV Corporation (NYSE: BKV) (“BKV” or the “Company”) today announced that it will report its third quarter 2024 operational and financial results before markets ...

BKV’s (NYSE:BKV – Get Free Report) quiet period is set to end on Tuesday, November 5th. BKV had issued 15,000,000 shares in its IPO on September 26th. The total size of the offering was $ ...

AiCuris Anti-infective Cures has launched a first-in-human Phase I trial of AIC468, an antisense oligonucleotide designed to ...

BKV Corporation (NYSE: BKV) (“BKV” or the “Company”) today announced that it will report its third quarter 2024 operational and financial results before ...

2010 - BKV Industries Ltd has appointed Sri. Yadlapalli Srinivasa Rao as Non-executive Independent Director of the Company with effect from April 29, 2010. 2012 - Email ID : investorskaktex@ ...

Previously as Chief Medical Officer at Vifor Pharma, Frits successfully led several assets through clinical development to ...

Putting shovels in the dirt, the team celebrated the start of an $82 million project expected to be completed by fall 2026.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...